AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • About Us
  • Committee
  • Future Dates of AdARRC™
  • History
    • AdARRC Academy™
    • AdARRC Summit™
    • Previous Speakers of AdARRC™
  • Annual Initiatives
    • Best Image Competition
    • Nominate a Trainee Winner
  • Sponsorship
    • Become a Sponsor or Exhibitor
    • Sponsors
×

Author: AdARRC™

 No advantage to 325 mg over 81 mg aspirin for persons with established cardiovascular disease (ADAPTABLE)
AdARRC™ June 20, 2022 Monday Weekly Update

No advantage to 325 mg over 81 mg aspirin for persons with established cardiovascular disease (ADAPTABLE)

Question What is the best dose of aspirin for secondary prevention in persons with established atherosclerotic cardiovascular disease? Conclusion There is no advantage to a 325-mg dose of aspirin for patients with established atherosclerotic cardiovascular disease (ASCVD), and people taking…
Read More
 How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
AdARRC™ May 9, 2022 Monday Weekly Update

How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?

Question How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults? Conclusion This study found no differences among ibuprofen, ketorolac, and diclofenac in the primary outcome of overall clinical improvement at 5…
Read More
 Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?
AdARRC™ April 4, 2022 Monday Weekly Update

Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?

Question Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis? Conclusion This study found no evidence that supports a benefit of PRP injections compared with saline placebo injections for improving function or…
Read More
 Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
AdARRC™ March 28, 2022 Monday Weekly Update

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed

Question What is the incidence and timing of recurrent herpes zoster in older adults? Conclusion The incidence of recurrent herpes zoster is comparable with the incidence of a first episode zoster infection, supporting the benefit of vaccination for individuals with…
Read More
 Evidence of benefit is lacking for low back pain relief with muscle relaxants
AdARRC™ March 21, 2022 Monday Weekly Update

Evidence of benefit is lacking for low back pain relief with muscle relaxants

Question Do muscle relaxants provide relief for nonspecific lower back pain? Conclusion Stick with nonsteroidal anti-inflammatories for the treatment of low back pain. Despite being used for almost 50 years to treat low back pain, the evidence supporting benzodiazepine or…
Read More
 Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)
AdARRC™ December 27, 2021 Monday Weekly Update

Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)

Question Is fluvoxamine effective in preventing hospitalizations in high-risk adults with COVID-19? Conclusion In this study, compared with placebo, fluvoxamine decreased hospitalizations in high-risk symptomatic adults with COVID-19. Reference Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al, for…
Read More
 Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+
AdARRC™ December 20, 2021 Monday Weekly Update

Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+

Question Does a booster dose provide clinical benefit against symptomatic infection and serious illness due to COVID-19 in persons 60 years and older who are fully vaccinated with the Pfizer-BioNTech vaccine?   Conclusion A booster (third) dose of the BNT162b2…
Read More
 Evidence of benefit is lacking for low back pain relief with muscle relaxants
AdARRC™ December 6, 2021 Monday Weekly Update

Evidence of benefit is lacking for low back pain relief with muscle relaxants

Question Do muscle relaxants provide relief for nonspecific lower back pain? Conclusion Stick with nonsteroidal anti-inflammatories for the treatment of low back pain. Despite being used for almost 50 years to treat low back pain, the evidence supporting benzodiazepine or…
Read More
 Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
AdARRC™ November 29, 2021 Monday Weekly Update

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed

Question What is the incidence and timing of recurrent herpes zoster in older adults? Conclusion The incidence of recurrent herpes zoster is comparable with the incidence of a first episode zoster infection, supporting the benefit of vaccination for individuals with…
Read More
 There is limited data on ivermectin in patients with COVID-19
AdARRC™ November 22, 2021 Monday Weekly Update

There is limited data on ivermectin in patients with COVID-19

Question Does ivermectin decrease mortality among persons hospitalized with COVID-19? Conclusion Although the data suggest that ivermectin decreases mortality among persons hospitalized with COVID-19, the messiness of the comparison groups and the concerns over data veracity indicate that more rigorous…
Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

 

© 2026 AdARRC™. All rights reserved